Tratamiento de la púrpura trombótica trombocitopénica mediante aféresis terapeútica en paciente con lupus eritematoso sistémico

Abstract

Thrombotic thrombocytopenic purpura (TTP) is an entity included in the concept of thrombotic microangiopathy1 consisting of the appearance of thrombi in the microcirculation that cause haemolysis, resulting in a decrease in red blood cells and platelets. There are multiple causes of TTP², including autoimmune diseases such as Systemic Lupus Erythematosus (SLE), although hereditary cases have also been described within the same family³. In children, an infectious process can occur two or three weeks before the PTT process is triggered. The cause of lupus ( SLE )⁴ is unknown and its incidence is ten times more frequent in women than in men, but it is included in an autoimmune disease influenced by genetic or environmental factors, giving symptoms such as inflammation of joints, kidneys, skin, etc. The treatment of TTP and SLE consists of the resolution of the precipitating cause (corticoids and immunosuppressants) associated with treatment with plasmapheresis.